These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30322396)

  • 1. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
    Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.
    Fluegen G; Avivar-Valderas A; Wang Y; Padgen MR; Williams JK; Nobre AR; Calvo V; Cheung JF; Bravo-Cordero JJ; Entenberg D; Castracane J; Verkhusha V; Keely PJ; Condeelis J; Aguirre-Ghiso JA
    Nat Cell Biol; 2017 Feb; 19(2):120-132. PubMed ID: 28114271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.
    Sosa MS; Parikh F; Maia AG; Estrada Y; Bosch A; Bragado P; Ekpin E; George A; Zheng Y; Lam HM; Morrissey C; Chung CY; Farias EF; Bernstein E; Aguirre-Ghiso JA
    Nat Commun; 2015 Jan; 6():6170. PubMed ID: 25636082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
    Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
    Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease.
    Siddappa CM; Watson MA; Pillai SG; Trinkaus K; Fleming T; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):45-56. PubMed ID: 23129172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
    Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
    BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
    Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
    Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
    Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
    BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway.
    Gao XL; Zheng M; Wang HF; Dai LL; Yu XH; Yang X; Pang X; Li L; Zhang M; Wang SS; Wu JB; Tang YJ; Liang XH; Tang YL
    BMC Cancer; 2019 Jul; 19(1):743. PubMed ID: 31357956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
    Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.
    Spiliotaki M; Mavroudis D; Kapranou K; Markomanolaki H; Kallergi G; Koinis F; Kalbakis K; Georgoulias V; Agelaki S
    Breast Cancer Res; 2014 Nov; 16(6):485. PubMed ID: 25432416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Borgen E; Synnestvedt M; Smaaland R; Naume B
    BMC Cancer; 2014 Jul; 14():514. PubMed ID: 25023626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.